Articles & Whitepapers

The medicine may be free. The tax risk is not.

Share With:

Authors: Dr Romina Oxborough • Dale Bushell

Published by: Maprium & VAT IT

VAT, customs and tariffs are becoming harder to separate from the day-to-day reality of running a global Managed Access Program.

From changing EU VAT requirements to US tariffs, the way medicines move across borders can create unexpected costs, compliance risks and missed recovery opportunities.

Our latest article, produced with VAT IT, explores what pharma teams need to understand — and why tax considerations should be built into MAP planning from the outset.

Download the PDF to explore the key issues, risks and opportunities for global Managed Access Programs.

More news and blogs

Blog

Managed Access Is Ready for Its Clinical Trials Moment

Why our CTO believes Managed Access is now where Clinical Trials were some years ago - and what lessons have been learnt

Blog

New Collaboration Helps Pharmaceutical Companies Generate Greater Value from Global Managed Access Programs

Partnership combines enterprise technology with real-world evidence expertise to maximise the strategic value of Managed Access Programs.

Take a personalized 15-minute tour

See Maprium in action

See Maprium in action

To request a demo, discuss your access challenges or learn more about Maprium, please use the secure form.